ERT, a US headquartered provider of clinical services and customisable medical devices, has appointed Linda Deal to lead its Health Outcomes Research initiatives.
Most recently Deal was the Immunology Patient Reported Outcomes (PRO) lead at Janssen Pharma, a division of Johnson & Johnson. Prior to this, she headed the PRO Centre in Global Health Outcomes Assessment (GHOA) at Wyeth Research, now part of Pfizer. She has also supported health economics and outcomes research for Wyeth, Research Triangle Institute, and Glaxo Welcome.
In the context of health outcomes research ERT’s ePRO solutions are said to offer the advantages of simplicity, mobility and immediacy of use over traditional paper-based methods.
The ePRO suite comprises an IVR solution (VIAPhone), a digital pen (VIAPen), a handheld device (VIAPad) and an Internet application (VIAWeb).
ERT hires Linda Deal
To head its Health Outcomes Research initiatives
You may also like
Regulatory
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
